Clinical and genetic predictions of early-onset cardiac toxicity in adjuvant chemotherapy for breast cancer

References

• Armenian SH , LacchettiC, BaracAet al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol.35(8), 893–911 (2017).
   PubMed Web of Science ®Google Scholar
• Zamorano JL , LancellottiP, RodriguezMuñoz Det al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. Eur. Heart J.37(36), 2768–2801 (2016).
   PubMed Web of Science ®Google Scholar
• Čelutkienė J , PudilR, LópezFernández Tet al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur. J. Heart Fail.22(9), 1504–1524 (2020).
   PubMed Web of Science ®Google Scholar
• Carver JR , SzaldaD, KyB. Asymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance. Semin. Oncol.40(2), 229–238 (2013).
   PubMed Web of Science ®Google Scholar
• Krajinovic M , ElbaredJ, DrouinSet al. Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia. Pharmacogenomics J.16(6), 530–535 (2016).
   PubMed Web of Science ®Google Scholar
• Stellitano A , FedeleR, BarillaS, IariaA, RaoCM, MartinoM. Chemotherapy and cardiotoxicity in hematologic malignancies. Curr. Cancer Drug Targets17(4), 311–324 (2017).
   PubMed Web of Science ®Google Scholar
• Curigliano G , CardinaleD, SuterTet al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann. Oncol.23, i155–i166 (2012).
   Web of Science ®Google Scholar
• Blanco JG , SunC, LandierWet al. Anthracycline-related cardiomyopathy after childhood cancer: role of polymorphisms in carbonyl reductase genes – a report from the Children’s Oncology Group. J. Clin. Oncol.30(13), 1415–1421 (2012).
   PubMed Web of Science ®Google Scholar
• Linschoten M , TeskeAJ, CramerMJ, vander Wall E, AsselbergsFW. Chemotherapy-related cardiac dysfunction: a systematic review of genetic variants modulating individual risk. Circ. Genom. Precis. Med.11(1), e1753 (2018).
   PubMed Web of Science ®Google Scholar
• Visscher H , RossCJD, RassekhSRet al. Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. J. Clin. Oncol.30(13), 1422–1428 (2012).
   PubMed Web of Science ®Google Scholar
• Liu B , AnT, LiMet al. The association between early-onset cardiac events caused by neoadjuvant or adjuvant chemotherapy in triple-negative breast cancer patients and some novel autophagy-related polymorphisms in their genomic DNA: a real-world study. Cancer Commun. (Lond).38(1), 71 (2018).
   PubMedGoogle Scholar
• Huang KM , HuS, SparreboomA. Drug transporters and anthracycline-induced cardiotoxicity. Pharmacogenomics19(11), 883–888 (2018).
   PubMed Web of Science ®Google Scholar
• Force T , KolajaKL. Cardiotoxicity of kinase inhibitors: the prediction and translation of preclinical models to clinical outcomes. Nat. Rev. Drug Discov.10(2), 111–126 (2011).
   PubMed Web of Science ®Google Scholar
• Schneider BP , ShenF, GardnerLet al. Genome-wide association study for anthracycline-induced congestive heart failure. Clin. Cancer Res.23(1), 43–51 (2017).
   PubMed Web of Science ®Google Scholar
• Henriksen PA . Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart104(12), 971–977 (2018).
   PubMed Web of Science ®Google Scholar
• Bursac Z , GaussCH, WilliamsDK, HosmerDW. Purposeful selection of variables in logistic regression. Source Code Biol. Med.3(1), 17 (2008).
   PubMedGoogle Scholar
• Slamon D , EiermannW, RobertNet al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med.365(14), 1273–1283 (2011).
   PubMed Web of Science ®Google Scholar
• Visscher H , RossCJD, RassekhSRet al. Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline-induced cardiotoxicity in children. Pediatr. Blood Cancer60(8), 1375–1381 (2013).
   PubMed Web of Science ®Google Scholar
• Stansberry WM , SwartM, MedeirosEB, SkaarTC, PrattVM. Report of confirmation of the rs7853758 and rs885004 haplotype in SLC28A3. Genet. Test. Mol Biomarkers22(11), 652–655 (2018).
   PubMed Web of Science ®Google Scholar
• Hertz DL , CaramMV, KidwellKMet al. Evidence for association of SNPs in ABCB1 and CBR3, but not RAC2, NCF4, SLC28A3 or TOP2B, with chronic cardiotoxicity in a cohort of breast cancer patients treated with anthracyclines. Pharmacogenomics17(3), 231–240 (2016).
   PubMed Web of Science ®Google Scholar
• Magdy T , JouniM, KuoHHet al. Identification of drug transporter genomic variants and inhibitors that protect against doxorubicin-induced cardiotoxicity. Circulation145(4), 279–294 (2021).
   PubMed Web of Science ®Google Scholar
• Tamargo-Gómez I , FernándezÁF, MariñoG. Pathogenic single nucleotide polymorphisms on autophagy-related genes. Int. J. Mol. Sci.21(21), 8196 (2020).
   PubMed Web of Science ®Google Scholar
• Alers S , WesselborgS, StorkB. ATG13. Autophagy10(6), 944–956 (2014).
   PubMed Web of Science ®Google Scholar
• Popelka H , KlionskyDJ. The molecular mechanism of Atg13 function in autophagy induction: what is hidden behind the data? Autophagy13(3), 449–451 (2017).
   PubMed Web of Science ®Google Scholar
• Jumper J , EvansR, PritzelAet al. Highly accurate protein structure prediction with AlphaFold. Nature596(7873), 583–589 (2021).
   PubMed Web of Science ®Google Scholar
• Carver JR , SzaldaD, KyB. Asymptomatic cardiac toxicity in long-term cancer survivors: defining the population and recommendations for surveillance. Semin. Oncol.40(2), 229–238 (2013).
   PubMed Web of Science ®Google Scholar
• Zardavas D , SuterTM, Van VeldhuisenDJet al. Role of troponins I and T and N-terminal prohormone of brain natriuretic peptide in monitoring cardiac safety of patients with early-stage human epidermal growth factor receptor 2-positive breast cancer receiving trastuzumab: a Herceptin adjuvant study cardiac marker substudy. J. Clin. Oncol.35(8), 878–884 (2017).
   PubMed Web of Science ®Google Scholar